• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

    5/8/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email

    SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025.

    Late Breaking Science Presentations

    Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms

    Presenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, Italy

    Date: May 17, 2025

    Topic: Chronic Heart Failure

    Session Title: Late Breaking Science in Heart Failure, Cardiomyopathies, Pulmonary Hypertension and Valvular Heart Disease

    Session Type: Late Breaking Science

    Session Time: 4:00 - 5:00 PM CEST

    Presentation Time: 4:20 PM CEST

    Location: Room 1

    Title: SEQUOIA-HCM: Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical Region

    Presenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of Glasgow

    Date: May 18, 2025

    Topic: Chronic Heart Failure

    Session Title: Hottest Trials and Trial Updates (2)

    Session Type: Late Breaking Science

    Session Time: 10:45 AM - 12:15 PM CEST

    Presentation Time: 11:11 AM CEST

    Location: Room 1

    Title: The Effect of Omecamtiv Mecarbil on Outcomes Analyzed Using the Win Ratio: An Exploratory Analysis of GALACTIC-HF

    Presenter: Kieran F. Docherty, Ph.D., Clinical Senior Lecturer in Heart Failure and Clinical Trials and Honorary Consultant Cardiologist, University of Glasgow

    Date: May 19, 2025

    Topic: Pharmacotherapy

    Session Title: Clinical Trials Updates in Medical Therapy

    Session Type: Late Breaking Science

    Session Time: 1:45 PM - 2:45 PM CEST

    Presentation Time: 2:25 PM CEST

    Location: Room 1

    ePoster Presentation

    Title: Associations Between Age and Sex and Cardiovascular Outcomes in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

    Presenter: Paulos Gebrehiwet, Ph.D., M.S., Senior Manager, Health Economics and Outcomes Research, Cytokinetics

    Date: May 17, 2025

    Topic: Clinical

    Session Title: ePosters in Myocardial Disease (2)

    Session Type: ePosters

    Session Time: 9:00 AM - 5:00 PM CEST

    Presentation Time: 1:26 PM CEST

    Location: ePosters Screen 14 - Research Gateway

    About Cytokinetics

    Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

    For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

    Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our other clinical trials, statements relating to the potential benefits of omecamtiv mecarbil, aficamten, or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

    CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

    Contact:

    Cytokinetics

    Diane Weiser

    Senior Vice President, Corporate Affairs

    (415) 290-7757



    Primary Logo

    Get the next $CYTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYTK

    DatePrice TargetRatingAnalyst
    4/24/2025$55.00Overweight
    Barclays
    2/7/2025$86.00Buy
    Citigroup
    1/22/2025$80.00Buy
    Stifel
    11/8/2024$80.00Outperform
    RBC Capital Mkts
    8/13/2024$85.00 → $60.00Buy → Neutral
    Goldman
    1/24/2024$61.00 → $92.00Buy → Neutral
    UBS
    1/5/2024$60.00 → $90.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2023$50.00Buy
    Goldman
    More analyst ratings

    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP Research & Development Malik Fady Ibraham exercised 2,000 shares at a strike of $10.60 and sold $70,020 worth of shares (2,000 units at $35.01) (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      5/6/25 4:37:08 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Commercial Officer Callos Andrew sold $146,793 worth of shares (4,002 units at $36.68), decreasing direct ownership by 6% to 60,687 units (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      5/5/25 6:21:57 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Blum Robert I sold $204,800 worth of shares (5,000 units at $40.96), decreasing direct ownership by 1% to 417,629 units (SEC Form 4)

      4 - CYTOKINETICS INC (0001061983) (Issuer)

      4/29/25 4:33:42 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Cytokinetics with a new price target

      Barclays initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $55.00

      4/24/25 7:43:15 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Cytokinetics with a new price target

      Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $86.00

      2/7/25 8:37:05 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Cytokinetics with a new price target

      Stifel initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $80.00

      1/22/25 7:34:24 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytokinetics Incorporated

      SC 13G - CYTOKINETICS INC (0001061983) (Subject)

      11/14/24 1:28:31 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

      SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

      11/12/24 2:21:36 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

      SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

      11/12/24 9:55:17 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cytokinetics Incorporated

      SCHEDULE 13G - CYTOKINETICS INC (0001061983) (Subject)

      5/7/25 10:37:54 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cytokinetics Incorporated

      10-Q - CYTOKINETICS INC (0001061983) (Filer)

      5/6/25 4:30:33 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CYTOKINETICS INC (0001061983) (Filer)

      5/6/25 4:05:10 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Financials

    Live finance-specific insights

    See more
    • Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

      PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte

      5/6/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics to Announce First Quarter Results on May 6, 2025

      SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q1 2025 Earnings Confe

      4/22/25 3:59:59 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

      Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and China Topline Results from MAPLE-HCM Expected in Q2 2025 Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2024 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2024. The company also provided full year 2025 financial guidance. "The fourth quarter of 2024 capped off

      2/27/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

      SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. Late Breaking Science Presentations Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild SymptomsPresenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, ItalyDate: May 17, 2025Topic: Chronic Heart FailureSe

      5/8/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics to Hold Annual Meeting of Stockholders

      SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company's headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present a company update. Stockholders of record at the close of business on March 24, 2025 are entitled to vote at Cytokinetics' Annual Meeting of Stockholders or to attend in person and submit questions to management. Stockholders wishing to vote m

      5/7/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

      PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte

      5/6/25 4:00:00 PM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYTK
    Leadership Updates

    Live Leadership Updates

    See more
    • Cytokinetics Names Robert E. Landry to Board of Directors

      Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici

      2/11/25 7:30:00 AM ET
      $CYTK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 1, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed

      3/1/24 6:47:00 PM ET
      $AIT
      $AL
      $APPS
      $ARCH
      Industrial Specialties
      Consumer Discretionary
      Diversified Commercial Services
      Multi-Sector Companies